Methylmalonic Acid (MMA) and B12 Deficiency: Why the Test Is Ordered and How to Read It

Methylmalonic acid (MMA) is a small molecule produced while your body breaks down certain amino acids and fatty acids. The enzyme that clears it — methylmalonyl-CoA mutase — needs vitamin B12 as a cofactor. When cells run short of usable B12 the enzyme slows, methylmalonyl-CoA piles up and is converted to methylmalonic acid, which spills into the blood and urine. That is why MMA is a functional marker: it does not measure how much B12 is present, it measures whether B12 is doing its job.

This matters because the standard serum B12 test has well-known blind spots. It counts all the cobalamin in blood, including the majority bound to a carrier protein (haptocorrin) that cells cannot use, and its sensitivity is imperfect — a meaningful share of people with genuine deficiency have a B12 result inside the reference range. MMA rises before hemoglobin falls or red cells enlarge, and it stays raised until B12 is replaced, so it catches early and hidden deficiency that the serum level misses.

Guidelines reserve MMA for the situations where the serum B12 result cannot settle the question. The most common trigger is a borderline B12, roughly 200–300 pg/mL (148–221 pmol/L), where deficiency is possible but not established; a raised MMA confirms it and a normal MMA makes it unlikely. The second is symptoms that fit deficiency despite a normal B12 — numbness or tingling in the hands and feet, unsteadiness, memory or mood changes, unexplained fatigue, a sore tongue, or large red cells on a blood count — because neurological damage can progress while the serum level looks reassuring.

MMA is also used to establish a true baseline in people already taking B12 supplements or receiving injections (which push the serum level up regardless of tissue status), to monitor response to treatment when the serum level is uninformative, in people at high risk of malabsorption — after bariatric or stomach surgery, with Crohn's or celiac disease, on long-term metformin or acid-suppressing drugs, older adults, vegans — and, in newborn screening and pediatrics, to detect the rare inherited disorder methylmalonic acidemia.

Serum MMA is reported in nanomoles per liter (nmol/L) or micromoles per liter (µmol/L; 1 µmol/L = 1,000 nmol/L). Reference intervals differ by laboratory: TestWell's catalog uses 0.000 – 378 nmol/L, the Labcorp interval; Quest reports approximately 87–318 nmol/L. A result above the printed upper limit is "high". In studies of B12 status, values above roughly 270–400 nmol/L (0.27–0.40 µmol/L) are the thresholds most often used to define metabolic deficiency, which is why a mildly raised value in an older adult with reduced kidney function is interpreted cautiously.

Result	Interpretation
MMA within range, B12 within range	B12 status adequate
MMA within range, B12 borderline (200–300 pg/mL)	Deficiency unlikely; recheck if symptoms develop
MMA raised, B12 borderline or low	Functional B12 deficiency confirmed — treat and look for the cause
MMA raised, B12 clearly normal	Possible tissue deficiency despite the serum level, or reduced kidney function — check creatinine/eGFR and consider active B12 or a trial of treatment
MMA very high (many times the upper limit)	Severe deficiency or, in infants and children, an inherited metabolic disorder — needs prompt evaluation

Urine MMA (reported per gram of creatinine) is an alternative that is less affected by kidney function; it is used less often in adults in the US but is a reasonable choice when kidney disease muddies the serum result.

MMA is cleared by the kidneys, so reduced kidney function is the main confounder: as eGFR falls, MMA rises even when B12 status is fine. This is why the result is read with a creatinine and eGFR, and why mildly raised values in older adults are so common. Other causes include older age itself (partly through kidney function), pregnancy, hypothyroidism, small-bowel bacterial overgrowth (gut bacteria produce propionate, an MMA precursor), dehydration and, rarely, the inherited enzyme and cofactor defects grouped as methylmalonic acidemia. Recent high intake of certain amino acids has a small effect; a fasting sample is not required but a consistent morning draw helps comparability.

Because of these, a single mildly raised MMA with a normal kidney function and a normal B12 is not automatically a deficiency; a homocysteine, an active B12 (holotranscobalamin) where available, or a repeat after correcting the likely confounder is how clinicians resolve it.

Test	What it measures	Strength	Limitation
Serum vitamin B12	Total cobalamin in blood	Inexpensive, widely available, the first-line test	Counts unusable carrier-bound B12; imperfect sensitivity; 200–300 pg/mL is indeterminate
Methylmalonic acid	Whether cells have enough usable B12	Specific to B12; rises early; unaffected by folate status	Raised by kidney impairment; specialty assay, slower turnaround
Homocysteine	A second metabolite that accumulates in B12 deficiency	Sensitive; also reflects folate and B6 status	Not specific: rises with folate deficiency, kidney disease, hypothyroidism and some genetic variants; needs a fasting sample
Active B12 (holotranscobalamin)	The fraction of B12 available to cells	Better reflects tissue status than total B12	Less widely available; ranges vary by lab

Read together, the pattern is informative: a high MMA with a high homocysteine points to B12 deficiency; a normal MMA with a high homocysteine points to folate (or B6) deficiency or another cause; a high MMA with a normal homocysteine is B12 deficiency or a kidney effect. The B12 deficiency panel draws all three from one tube for this reason.

A high MMA with a low or borderline B12 confirms deficiency, and two things follow. The first is treatment, chosen by a clinician: B12 is replaced orally or by injection depending on the cause and severity, and people with pernicious anemia or after ileal surgery generally need it lifelong. Neurological symptoms are treated without delay because they can become permanent. The second is finding the cause. Intrinsic factor antibodies (and sometimes parietal cell antibodies) identify pernicious anemia; a medication review catches metformin and acid suppressants; celiac serology and, when indicated, gastrointestinal evaluation look for malabsorption; diet history covers vegan and restricted eating; and nitrous oxide use is asked about in younger adults. Folate is checked and corrected at the same time, because treating folate alone can mask B12 deficiency while nerve damage continues.

MMA normalizes within weeks of effective B12 replacement. A repeat MMA after about 3 months confirms the response; a value that stays raised despite treatment points to ongoing malabsorption, poor adherence to oral therapy, kidney disease or another cause. A blood count within a few weeks shows whether any anemia or large red cells are resolving.

MMA is a standard blood draw with no fasting requirement. It is measured by mass spectrometry at a specialty laboratory, so results typically take longer than routine tests — allow about a week or more. Recent B12 supplementation lowers MMA (that is the point of treatment), so if you want a true baseline, test before starting or tell the interpreting clinician what you take. You can order MMA alone or as part of the B12 deficiency panel online through TestWell; a licensed physician reviews the order, you visit a nearby Quest or Labcorp patient service center, and results appear in your portal. Your own clinician can also order it, and it is commonly added when a serum B12 returns in the gray zone.